The MS4A4A and MS4A6A genes, located in the MS4A gene cluster on chromosome 11q12, have emerged as significant Alzheimer's disease risk genes through genome-wide association studies. A groundbreaking 2026 study published in Neuron revealed that these two genes cooperate to negatively regulate TREM2, a critical receptor on microglia that mediates amyloid clearance and inflammatory responses. This cooperative regulatory mechanism represents a novel therapeutic target for AD intervention.
The discovery that MS4A4A and MS4A6A cooperate to regulate TREM2 builds upon earlier findings showing that:
- Genetic variants in the MS4A gene cluster influence AD risk
- MS4A4A interacts with TREM2 as a functional receptor complex
- MS4A4A expression affects microglial function and amyloid clearance
The new study demonstrates that while MS4A4A and TREM2 can form a direct complex, the primary mechanism of MS4A4A's effect on TREM2 is indirect—mediated through MS4A6A and the DAP12 co-receptor.
The MS4A gene cluster on chromosome 11q12.2 contains multiple genes including:
| Gene |
Position |
Expression |
AD Association |
| MS4A4A |
11q12.2 |
Microglia |
Risk gene |
| MS4A6A |
11q12.2 |
Microglia |
Risk gene |
| MS4A7 |
11q12.2 |
Low |
Some association |
| MS4A2 |
11q12.2 |
Mast cells |
No AD link |
Multiple GWAS-identified variants in this locus affect:
- CSF soluble TREM2 (sTREM2) levels
- Microglial activation states
- Disease progression and risk
flowchart TD
A["MS4A4A Expression"] --> B["MS4A4A Protein"]
B --> C["MS4A4A interacts with MS4A6A"]
C --> D["MS4A6A Stabilization"]
D --> E["MS4A6A-DAP12 Complex Formation"]
E --> F["DAP12 Blocked from TREM2"]
F --> G["Reduced TREM2 Signaling"]
G --> H["Impaired Microglial Function"]
H --> I1["Reduced Phagocytosis"]
H --> I2["Decreased Microglial Viability"]
H --> I3["Impaired Lysosomal Function"]
H --> I4["Altered Inflammatory Response"]
I1 --> J["Amyloid Accumulation"]
I2 --> K["Neurodegeneration"]
I3 --> J
I4 --> K
- MS4A4A protects MS4A6A from degradation
- Stabilized MS4A6A can form complexes
- This is the key regulatory step
- MS4A6A binds to DAP12 (TYROBP)
- DAP12 normally co-receptors with TREM2
- MS4A6A competes for DAP12 availability
- Results in reduced TREM2-DAP12 signaling
When TREM2-DAP12 signaling is reduced:
- Phagocytosis impaired (reduced Aβ clearance)
- Microglial viability decreased
- Lysosomal function compromised
- Inflammatory response dysregulated
The 2026 Neuron paper used multiple approaches:
- Knockout models: MS4A4A and MS4A6A genetic deletion
- Overexpression studies: Increased expression to test effects
- Degrading antibodies: Protein clearance to assess function
- Multiple species: Macrophages, microglia, non-human primates, mice
| Finding |
Species |
Implication |
| MS4A4A stabilizes MS4A6A |
Human/mouse |
Key regulatory step |
| MS4A6A blocks DAP12 |
Cell culture |
Competitive inhibition |
| Knockout increases TREM2 |
Mouse models |
Negative regulation confirmed |
| Overexpression reduces TREM2 |
Multiple systems |
Dose-dependent effect |
Prior research established that MS4A4A can directly interact with TREM2:
- Direct protein-protein binding on microglial surface
- Co-clustering in lipid rafts
- Cooperative signaling in phagocytosis
- Regulation of microglial survival pathways
The new study shows:
- The dominant effect of MS4A4A on TREM2 is indirect
- MS4A4A's primary role is protecting MS4A6A
- MS4A6A then blocks DAP12 from TREM2
- This represents a two-step regulatory pathway
| Approach |
Target |
Strategy |
| MS4A4A inhibition |
Increase TREM2 |
Enhance phagocytosis |
| MS4A6A inhibition |
Increase TREM2 |
Enhance phagocytosis |
| MS4A4A-MSA6A disruptor |
Block interaction |
Release TREM2 |
| Direct TREM2 agonist |
Bypass regulation |
Activate signaling |
- TREM2 required for transition to activated states
- MS4A4A/MS4A6A negatively regulate this transition
- TREM2-dependent activation
- MS4A4A/MS4A6A limit DAM formation and function
| Microglial Function |
Effect of MS4A4A/MS4A6A |
| Viability |
Reduced |
| Phagocytosis |
Impaired |
| Lysosomal function |
Compromised |
| Metabolic fitness |
Decreased |
| Inflammatory response |
Dysregulated |
Rare variants in TREM2 (R47H, R62H, Y38C) cause:
- ~2-4x increased AD risk
- Impaired ligand binding
- Reduced phagocytosis
- Similar phenotype to MS4A4A/MS4A6A overexpression
- Genetic variants increase AD risk
- Mechanism: reduced TREM2 signaling
- Phenotype: similar to TREM2 LOF variants
- Potential for therapeutic modulation
The MS4A4A-MS4A6A-TREM2 axis offers multiple intervention points:
flowchart LR
subgraph Current["Therapeutic Approaches"]
T1["TREM2 Agonist Antibodies"]
T2["Gene Therapy"]
end
subgraph Novel["MS4A-Targeted Approaches"]
N1["MS4A4A Antagonists"]
N2["MS4A6A Antagonists"]
N3["Dissociating MS4A4A-MS4A6A"]
end
N1 --> R["↑ TREM2 Signaling"]
N2 --> R
N3 --> R
T1 --> R
T2 --> R
R --> B["Enhanced Microglial Function"]
B --> C["↓ Amyloid Accumulation"]
- Upstream intervention: Modulate before TREM2
- Combination potential: Can pair with TREM2 agonists
- Cell-type specificity: Microglia-expressed
- Genetic validation: GWAS-confirmed AD risk genes
- Balancing act: Too much TREM2 activation may cause inflammation
- Timing: Early vs. late-stage intervention
- Specificity: Targeting the right gene/products
- Delivery: Brain penetration requirements
The MS4A gene family has undergone significant expansion in humans compared to other mammals. The cluster on chromosome 11q12.2 contains at least 10 MS4A genes in humans, many of which show brain-specific or immune cell expression. This expansion coincided with increased complexity of microglial regulation in primate brains.
| Gene |
Brain Expression |
Immune Cell Expression |
Tissue Distribution |
| MS4A4A |
High |
Microglia-specific |
Brain, spinal cord |
| MS4A6A |
High |
Microglia-specific |
Brain |
| MS4A7 |
Low |
Some |
Lung, spleen |
| MS4A2 |
Very low |
Mast cells |
Various |
MS4A4A and MS4A6A show conservation across mammalian species, with orthologous genes in mice, rats, and non-human primates. However, regulatory elements and splicing patterns show species-specific differences. This has implications for translational research using mouse models.
MS4A proteins are typical 4-transmembrane domain proteins with extracellular loops and intracellular termini. The structure includes:
- N-terminal cytoplasmic domain: Contains potential phosphorylation sites
- Extracellular loop 1: Variable region involved in ligand binding
- Transmembrane domains: Four alpha-helices anchoring the protein
- Extracellular loop 2: Larger loop with potential protein interaction sites
- C-terminal cytoplasmic domain: Contains motifs for signaling
MS4A4A and MS4A6A undergo several post-translational modifications:
- N-glycosylation: In extracellular domains
- Phosphorylation: In cytoplasmic domains
- Palmitoylation: For membrane association
- Dimerization: For functional complex formation
TREM2 signaling through DAP12 initiates multiple downstream cascades:
flowchart TD
A["TREM2-DAP12 Complex"] --> B["SYK Activation"]
B --> C1["PI3K/Akt Pathway"]
B --> C2["MAPK/ERK Pathway"]
B --> C3["NF-κB Pathway"]
C1 --> D1["Cell Survival"]
C1 --> D2["Metabolic Regulation"]
C2 --> D3["Proliferation"]
C2 --> D4["Differentiation"]
C3 --> D5["Inflammatory Response"]
C3 --> D6["Gene Expression"]
D1 --> E["Microglial Survival"]
D2 --> E
D3 --> F["Activated Microglia"]
D4 --> F
D5 --> G1["Pro-inflammatory"]
D5 --> G2["Anti-inflammatory"]
D6 --> F
TREM2 activation regulates multiple microglial functions:
| Function |
TREM2 Effect |
MS4A4A/MS4A6A Effect |
| Phagocytosis |
↑ Strong |
↓ Via TREM2 reduction |
| Cell survival |
↑ Pro-survival |
↓ Via TREM2 reduction |
| Metabolic fitness |
↑ Enhanced |
↓ Via TREM2 reduction |
| Cytokine production |
Modulated |
Altered pattern |
| Migration |
↑ Chemotaxis |
↓ Reduced |
The MS4A4A-MS4A6A-TREM2 axis operates differently across AD stages:
Early Stage:
- MS4A4A/MS4A6A expression may be protective
- Negative regulation limits excessive inflammation
- TREM2 activation promotes amyloid clearance
Moderate Stage:
- Regulated TREM2 becomes insufficient
- Microglial activation states shift
- Amyloid clearance becomes impaired
Late Stage:
- Chronic dysregulation contributes to neuroinflammation
- TREM2-dependent functions decline
- Neurodegeneration accelerates
The MS4A4A-MS4A6A axis may have relevance beyond AD:
Parkinson's Disease:
- Microglial involvement in PD pathogenesis
- TREM2 variants may affect risk
- Potential for therapeutic modulation
ALS:
- Microglial contribution to disease
- TREM2 in inflammatory responses
- MS4A gene involvement uncertain
FTD:
- TREM2 variants in FTD risk
- MS4A genes less studied
- Potential mechanistic overlap
¶ Antibody Approaches
- Block MS4A4A stabilization of MS4A6A
- Increase available DAP12 for TREM2
- Enhance TREM2 signaling indirectly
- Requires brain penetration
- Prevent DAP12 sequestration
- Free DAP12 for TREM2
- Direct mechanism
- May have fewer off-target effects
- Direct activation of TREM2
- Bypass MS4A regulation
- Currently in clinical development
- Potential combination with MS4A targeting
Targeting MS4A4A-MS4A6A interaction:
- Interface blockers: Disrupt protein-protein binding
- Degraders: Promote MS4A6A degradation
- Expression inhibitors: Reduce MS4A transcription
- CRISPR editing to correct risk variants
- siRNA to reduce MS4A expression
- AAV delivery to microglia
Treatment Response Markers:
- CSF sTREM2 levels
- Microglial activation markers
- Amyloid PET changes
- Cognitive measures
Patient Selection:
- MS4A genotypes
- TREM2 variant status
- Disease stage
- Amyloid burden
Key challenges in translating findings:
| Aspect |
Human |
Mouse |
Implication |
| Gene cluster |
10+ genes |
~6 genes |
Different regulation |
| Expression |
Microglia-high |
Mixed |
Translation |
| Protein sequence |
80% identical |
~80% |
Function conserved |
| Response to injury |
Complex |
Simplified |
Model limitations |
Measuring Function:
- MS4A4A-MS4A6A interaction assays
- TREM2 signaling readouts
- Microglial functional assays
- In vivo imaging
Model Limitations:
- Cell line models oversimplify
- Primary cells limited
- Animal models incomplete
- Cross-species differences
- What determines the balance between beneficial and harmful MS4A4A/MS4A6A effects?
- How do MS4A4A and MS4A6A variants affect disease progression?
- Can timing of intervention improve outcomes?
- What combination approaches will be most effective?
- Develop biomarkers for patient selection
- Establish optimal treatment windows
- Determine combination therapy approaches
- Monitor treatment response